Journal of Shandong University (Health Sciences) ›› 2021, Vol. 59 ›› Issue (8): 32-37.doi: 10.6040/j.issn.1671-7554.0.2021.0877
Previous Articles Next Articles
DENG Xiaohui1,2, GUO Ling1,2
CLC Number:
[1] Mak JSM, Chung CHS, Chung JPW, et al. The effect of endometrial scratch on natural-cycle cryopreserved embryo transfer outcomes: a randomized controlled study [J]. Reprod Biomed Online, 2017, 35(1): 28-36. [2] Thornhill AR, deDie-Smulders CE, Geraedts JP, et al. ESHRE PGD Consortium 'Best practice guidelines for clinical preimplantation genetic diagnosis(PGD)and preimplantation genetic screening(PGS)' [J]. Hum Reprod, 2005, 20(1): 35-48. [3] Coughlan C, Ledger W, Wang Q, et al. Recurrent implantation failure: definition and management [J]. Reprod Biomed Online, 2014, 28(1): 14-38. [4] Cakiroglu Y, Tiras B. Determining diagnostic criteria and cause of recurrent implantation failure [J]. Curr Opin Obstet Gynecol, 2020, 32(3): 198-204. [5] Bashiri A, Halper KI, Orvieto R. Recurrent Implantation Failure-update overview on etiology, diagnosis, treatment and future directions [J]. Reprod Biol Endocrinol, 2018, 16(1): 121. [6] 刘茜桐, 卢娜, 李佩, 等. 胚胎反复种植失败的免疫学预测指标[J]. 中华生殖与避孕杂志, 2018, 38(6): 517-520. [7] Lu HQ, Hu R. The role of immunity in the pathogenesis and development of pre-eclampsia [J]. Scand J Immunol, 2019, 90(5): e12756. [8] Liang PY, Diao LH, Huang CY, et al. The pro-inflammatory and anti-inflammatory cytokine profile in peripheral blood of women with recurrent implantation failure [J]. Reprod Biomed Online, 2015, 31(6): 823-826. [9] Kofod L, Lindhard A, Bzorek M, et al. Endometrial immune markers are potential predictors of normal fertility and pregnancy after in vitro fertilization [J]. Am J Reprod Immunol, 2017, 78(3):e12684. [10] 汪希鹏. 复发性流产与反复种植失败的病因和治疗新观点[J]. 中华妇产科杂志, 2019, 54(12): 793-796. WANG Xipeng. New opinions in etiology and therapy of recurrent spontaneous abortion and recurrent implantation failure[J]. Chinese Journal of Obstetrics and Gynecology, 2019, 54(12): 793-796. [11] Ledee-Bataille N, Bonnet-Chea K, Hosny G, et al. Role of the endometrial tripod interleukin-18, -15, and -12 in inadequate uterine receptivity in patients with a history of repeated in vitro fertilization-embryo transfer failure [J]. Fertil Steril, 2005, 83(3): 598-605. [12] Zhang T, Huang C, Du Y, et al. Successful treatment with intrauterine delivery of dexamethasone for repeated implantation failure[J]. Am J Reprod Immunol, 2017, 78(6):e12766. doi: 10.1111/aji.12766. [13] Ledee N, Prat-Ellenberg L, Petitbarat M, et al. Impact of prednisone in patients with repeated embryo implantation failures: beneficial or deleterious? [J]. J Reprod Immunol, 2018, 127(1): 11-15. [14] de Moreuil C, Alavi Z, Pasquier E. Hydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage [J]. Br J Clin Pharmacol, 2020, 86(1): 39-49. [15] Mekinian A, Lazzaroni MG, Kuzenko A, et al. The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a European multicenter retrospective study [J]. Autoimmun Rev, 2015, 14(6): 498-502. [16] Belizna C, Pregnolato F, Abad S, et al. HIBISCUS: hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome [J]. Autoimmun Rev, 2018, 17(12): 1153-1168. [17] Schreiber K, Breen K, Cohen H, et al. HYdroxychloroquine to improve pregnancy outcome in women with anTIphospholipid antibodies(HYPATIA)protocol: a multinational randomized controlled trial of hydroxychloroquine versus placebo in addition to standard treatment in pregnant women with antiphospholipid syndrome or antibodies [J]. Semin Thromb Hemost, 2017, 43(6): 562-571. [18] Mekinian A, Vicaut E, Cohen J, et al. Hydroxychloroquine to obtain pregnancy without adverse obstetrical events in primary antiphospholipid syndrome: French phase II multicenter randomized trial, HYDROSAPL [J]. Gynecol Obstet Fertil Senol, 2018, 46(7-8): 598-604. [19] Mekinian A, Cohen J, Alijotas-Reig J, et al. Unexplained recurrent miscarriage and recurrent implantation failure: is there a place for immunomodulation? [J]. Am J Reprod Immunol, 2016, 76(1): 8-28. [20] Ghasemnejad-Berenji H, Ghaffari Novin M, Hajshafiha M, et al. Immunomodulatory effects of hydroxychloroquine on Th1/Th2 balance in women with repeated implantation failure [J]. Biomed Pharmacother, 2018, 107(1): 1277-1285. [21] Forsse A, Nielsen TH, Nygaard KH, et al. Cyclosporin A ameliorates cerebral oxidative metabolism and infarct size in the endothelin-1 rat model of transient cerebral ischaemia [J]. Sci Rep, 2019, 9(1): 3702. [22] Zhang T, Li Z, Liu T, et al. Cyclosporine a drug-delivery system for high-risk penetrating keratoplasty: Stabilizing the intraocular immune microenvironment [J]. PLoS One, 2018, 13(5): e0196571. [23] Du MR, Dong L, Zhou WH, et al. Cyclosporin a improves pregnancy outcome by promoting functions of trophoblasts and inducing maternal tolerance to the allogeneic fetus in abortion-prone matings in the mouse [J]. Biol Reprod, 2007, 76(5): 906-914. [24] Ling Y, Huang Y, Chen C, et al. Low dose Cyclosporin A treatment increases live birth rate of unexplained recurrent abortion — initial cohort study [J]. Clin Exp Obstet Gynecol, 2017, 44(2): 230-235. [25] Zhou WH, Du MR, Dong L, et al. Cyclosporin A increases expression of matrix metalloproteinase 9 and 2 and invasiveness in vitro of the first-trimester human trophoblast cells via the mitogen-activated protein kinase pathway [J]. Hum Reprod, 2007, 22(10): 2743-2750. [26] Nakagawa K, Kwak-Kim J, Ota K, et al. Immunosuppression with tacrolimus improved reproductive outcome of women with repeated implantation failure and elevated peripheral blood TH1/TH2 cell ratios [J]. Am J Reprod Immunol, 2015, 73(4): 353-361. [27] Azizi R, Ahmadi M, Danaii S, et al. Cyclosporine A improves pregnancy outcomes in women with recurrent pregnancy loss and elevated Th1/Th2 ratio [J]. J Cell Physiol, 2019, 234(4): 19039-19047. [28] Nakagawa K, Kwak-Kim J, Kuroda K, et al. Immunosuppressive treatment using tacrolimus promotes pregnancy outcome in infertile women with repeated implantation failures [J]. Am J Reprod Immunol, 2017, 78(3): e12682. [29] Perales-Puchalt A, Vila Vives JM, Lopez Montes J, et al. Pregnancy outcomes after kidney transplantation-immunosuppressive therapy comparison [J]. J Matern Fetal Neonatal Med, 2012, 25(8): 1363-1366. [30] Akturk S, Celebi ZK, Erdogmus S, et al. Pregnancy after kidney transplantation: outcomes, tacrolimus doses, and trough levels [J]. Transplant Proc, 2015, 47(5): 1442-1444. [31] Ahmadi M, Aghdam SA, Nouri M, et al. Intravenous immunoglobulin(IVIG)treatment modulates peripheral blood Th17 and regulatory T cells in recurrent miscarriage patients: non randomized, open-label clinical trial [J]. Immunol Lett, 2017, 192(1): 12-19. [32] Nyborg KM, Kolte AM, Larsen EC, et al. Immunomodulatory treatment with intravenous immunoglobulin and prednisone in patients with recurrent miscarriage and implantation failure after in vitro fertilization/intracytoplasmic sperm injection [J]. Fertil Steril, 2014, 102(6): 1650-1655. [33] Ramos-Medina R, Garcia-Segovia A, Gil J, et al. Experience in IVIg therapy for selected women with recurrent reproductive failure and NK cell expansion [J].Am J Reprod Immunol, 2014, 71(5): 458-466. [34] Ahmadi M, Abdolmohammadi-Vahid S, Ghaebi M, et al. Regulatory T cells improve pregnancy rate in RIF patients after additional IVIG treatment [J]. Syst Biol Reprod Med, 2017, 63(6): 350-359. [35] Han AR, Lee SK. Immune modulation of i.v. immunoglobulin in women with reproductive failure [J]. Reprod Med Biol, 2018, 17(2): 115-124. [36] Check JH, Liss JR, Check ML, et al. Lymphocyte immunotherapy can improve pregnancy outcome following embryo transfer(ET)in patients failing to conceive after two previous ET [J]. Clin Exp Obstet Gynecol, 2005, 32(1): 21-22. [37] Kamath MS, Chittawar PB, Kirubakaran R, et al. Use of granulocyte-colony stimulating factor in assisted reproductive technology: a systematic review and meta-analysis [J]. Eur J Obstet Gynecol Reprod Biol, 2017, 214(1): 16-24. [38] Arefi S, Fazeli E, Esfahani M, et al. Granulocyte-colony stimulating factor may improve pregnancy outcome in patients with history of unexplained recurrent implantation failure: an RCT [J]. Int J Reprod Biomed, 2018, 16(5): 299-304. [39] Kalem Z, Namli Kalem M, Bakirarar B, et al. Intrauterine G-CSF administration in recurrent implantation failure(RIF)[J]. An Rct Sci Rep, 2020, 10(1): 5139. [40] Liu X, Ma D, Wang W, et al. Intrauterine administration of human chorionic gonadotropin improves the live birth rates of patients with repeated implantation failure in frozen-thawed blastocyst transfer cycles by increasing the percentage of peripheral regulatory T cells [J]. Arch Gynecol Obstet, 2019, 299(4): 1165-1172. [41] Xie H, Zeng H, He D, et al. Effect of intrauterine perfusion of human chorionic gonadotropin before embryo transfer after two or more implantation failures: a systematic review and meta-analysis [J]. Eur J Obstet Gynecol Reprod Biol, 2019, 243(1): 133-138. [42] Volovsky M, Healey M, MacLachlan V, et al. Should intrauterine human chorionic gonadotropin infusions ever be used prior to embryo transfer? [J]. J Assist Reprod Genet, 2018, 35(2): 273-278. [43] Yu N, Zhang B, Xu M, et al. Intrauterine administration of autologous peripheral blood mononuclear cells(PBMCs)activated by HCG improves the implantation and pregnancy rates in patients with repeated implantation failure: a prospective randomized study [J]. Am J Reprod Immunol, 2016, 76(3): 212-216. [44] Heinz H P, Loos M. Activation of the first component of complement, C1: comparison of the effect of sixteen different enzymes on serum C1 [J]. Immunobiology, 1983, 165(2): 175-185. [45] Winger EE, Reed JL, Ashoush S, et al. Degree of TNF-alpha/IL-10 cytokine elevation correlates with IVF success rates in women undergoing treatment with Adalimumab(Humira)and IVIG [J]. Am J Reprod Immunol, 2011, 65(6): 610-618. |
[1] | QIN Jing, YANG Fei, CHEN Qian, XIA Handai, LIU Yanguo, WANG Xiuwen. A network meta-analysis of first-line treatment options for patients with advanced driver-gene wild-type and PD-L1 negative non-squamous non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 74-82. |
[2] | GAO Huijiang, WEI Yucheng. Minimally invasive sleeve lobectomy: opportunities and challenges in the era of immunotherapy [J]. Journal of Shandong University (Health Sciences), 2022, 60(11): 23-27. |
[3] | Jinming YU,Weiwei YAN,Dawei CHEN. New practice of radio-immunotherapy for lung cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 1-8. |
[4] | PANG Zhaofei, LIU Yong, ZHAO Xiaogang, YAN Tao, CHEN Xiaowei, DU Jiajun. Construction of a stemness-based scoring model predicting the efficacy of immunotherapy in lung adenocarcinoma based on public databases [J]. Journal of Shandong University (Health Sciences), 2021, 59(11): 19-28. |
[5] | Gang LI,Hao XUE,Wei QIU,Rongrong ZHAO. Research advances in the formation of glioma immunosuppressive microenvironment [J]. Journal of Shandong University (Health Sciences), 2020, 1(8): 67-73. |
[6] | WANG Zhao. Advances in the clinical treatment of hemophagocytic lymphohistiocytosis [J]. Journal of Shandong University (Health Sciences), 2019, 57(7): 44-49. |
[7] | WU Depei, CHEN Xiaochen. Current situation and prospect of immunotherapy for lymphoma [J]. Journal of Shandong University (Health Sciences), 2019, 57(7): 13-20. |
[8] | HUANG Xiaojun. Advances of cellular immunotherapy for hematologic malignancies [J]. Journal of Shandong University (Health Sciences), 2019, 57(7): 1-5. |
[9] | CHEN Shiling, ZHOU Xingyu. Clinical research advances on premature ovarian insufficiency [J]. Journal of Shandong University (Health Sciences), 2018, 56(4): 1-7. |
[10] | ZHENG Min, ZHANG Lan. Current situation and development trend of CAR-T in anti-tumor research [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(11): 1-6. |
[11] | ZHANG Lin1, HOU Yan-hong1, ZHANG Jian2, HU Jing1, ZHANG Jing1. Experimental study of anti-CD3/anti-EGFR bispecific antibody therapeutic activity against pancreatic cancer cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(1): 15-19. |
[12] |
JIANG Yu-xin, MA Yu-cheng, LI Chao-pin.
Effect of immunotherapy on asthma mice with chimeric allergens derived from the major allergen group 2 genes of dust mites [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(10): 50-. |
[13] | LI Xue-jiao. The efficacy of specific immunotherapy combined with Yupingfeng granules for atopic dermatitis [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(7): 144-146. |
[14] | YU Yuan1, LI Yan1, RONG Fengnian2, LIANG Jing1, LIU Xiaolin1, WANG Fuli1. Therapy effect of auto-CIK on regulatory T cells in ovarian neoplasms patients [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(5): 101-104. |
[15] | ZHANG Bei1,2, YAN Li2, ZHOU Ting2, RONG Feng-nian2. Short-term curative efficacy of cytokine-induced killer cells on patients with gynecological malignant carcinoma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(11): 121-. |
|